In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.
In May 2016, letters were sent regarding:
Nexplanon (etonogestrel) implants have been found rarely in the vasculature and lung: an update regarding possible risks and complications regarding insertion, localisation and removal (Nexplanon letter to healthcare professionals May 2016)—see also article in this issue
ERWINASE: notice of special handling instructions—vials of ERWINASE from batch 174g should be used with a 5-micron filter needle (ERWINASE letter to healthcare professionals May 2016)
Article citation: Drug Safety Update vol 9 issue 11, June 2016: 4.
15 June 2016
Medicines and Healthcare products Regulatory Agency
Obstetrics, gynaecology and fertility
Don’t include personal or financial information like your National Insurance number or credit card details.